万赛维在国内获批上市没？

Indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). Valganciclovir hydrochloride tablets are suitable for preventing CMV infection in high-risk solid organ transplant patients. When Vancevi is used to prevent CMV infection in organ transplants in adult patients, for kidney transplant patients, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 200 days after transplantation. For patients who have received a solid organ transplant other than a kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Has Vancevi been approved for listing in China?

It is reported that Vancevi was launched in China in 2006 and its indications include induction treatment of CMV retinitis, maintenance treatment of CMV retinitis and prevention of CMV infection in transplant patients. However, because this drug is an imported original drug in China, it is relatively expensive. Domestic valganciclovir hydrochloride tablets are available in sizes of 450 mg to 60 tablets per box and are priced at approximately US$2,250.

In order to reduce medical expenses, many patients choose to buy Vancevir sold by Roche in India. The price is much cheaper than in China. India's Vancevir (valgancilovir hydrochloride tablets, valgansiklovir) 450mg*60 tablets/box is priced at about US$750. Due to the floating exchange rate, the price is not fixed. Please consult Medical Travel for specific prices.

Precautions: Hematological disorders: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia and bone marrow failure, including aplastic anemia. May occur at any time during treatment and worsen with continued use; cell counts usually begin to recover within 3-7 days of stopping treatment. Do not use if the absolute neutrophil count is <500 cells/MM3, platelet count <25,000/m3, or hemoglobin <8 g/dl; use with caution in patients with myelosuppression, cytopenia, or patients receiving myelosuppressive drugs/radiation. Monitor CBC and platelet counts at baseline and frequently during treatment, especially in infants and patients with renal impairment, patients with prior drug-induced leukopenia, and patients with neutrophil counts <1000 cells/mm3 at the start of treatment.